Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Monday, May 5th. Analysts expect Pliant Therapeutics to post earnings of ($0.72) per share for the quarter.
Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported ($0.82) earnings per share for the quarter, topping analysts' consensus estimates of ($0.99) by $0.17. On average, analysts expect Pliant Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Pliant Therapeutics Price Performance
Shares of PLRX traded up $0.07 during trading hours on Friday, reaching $1.69. The stock had a trading volume of 762,075 shares, compared to its average volume of 1,071,979. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.26 and a current ratio of 10.26. Pliant Therapeutics has a 12 month low of $1.10 and a 12 month high of $16.52. The stock has a market capitalization of $103.74 million, a PE ratio of -0.51 and a beta of 1.46. The company's 50-day moving average is $1.58 and its two-hundred day moving average is $8.31.
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on the company. Wells Fargo & Company cut their price target on Pliant Therapeutics from $4.00 to $3.00 and set an "equal weight" rating on the stock in a research note on Tuesday, March 4th. Leerink Partnrs lowered shares of Pliant Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, March 3rd. Oppenheimer restated a "market perform" rating on shares of Pliant Therapeutics in a research report on Monday, February 10th. Canaccord Genuity Group reiterated a "hold" rating and set a $4.00 price target (down previously from $43.00) on shares of Pliant Therapeutics in a report on Monday, February 10th. Finally, Needham & Company LLC restated a "hold" rating and issued a $10.00 price objective on shares of Pliant Therapeutics in a report on Tuesday, March 4th. Twelve equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $13.31.
Get Our Latest Stock Analysis on PLRX
About Pliant Therapeutics
(
Get Free Report)
Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.
Further Reading
Before you consider Pliant Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pliant Therapeutics wasn't on the list.
While Pliant Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
